What Is BPC-157?
BPC-157 is a synthetic peptide made up of 15 amino acids, derived from a sequence found in a protein present in gastric juice. It is studied extensively in preclinical (animal and cell) research and is not an approved drug.
The short answer
BPC-157 — short for "Body Protection Compound 157" — is a lab-synthesized peptide fragment. Its sequence is based on a partial sequence of a naturally occurring protein identified in the stomach. In research settings it is typically supplied as a lyophilized (freeze-dried) powder and characterized by mass spectrometry and HPLC for identity and purity. It has been the subject of a large body of animal studies, but human clinical evidence is limited, and it has not been approved by the FDA for any use.
Composition and specifications
| Compound | BPC-157 (pentadecapeptide) |
|---|---|
| Length | 15 amino acids |
| CAS number | 137525-51-0 |
| Molecular weight | 1419.55 g/mol |
| Purity (typical) | ≥99% by HPLC |
| Identity | Confirmed by mass spectrometry |
| Form | White lyophilized powder; water-soluble |
Values above reflect the compound's published specification. As with any research material, the definitive confirmation of identity and purity for a given lot is the mass-spectrometry and HPLC data on its Certificate of Analysis.
What is it made of?
Structurally, BPC-157 is a chain of 15 amino acids (a "pentadecapeptide"). Because it is produced synthetically rather than extracted, research-grade material is made to a defined sequence and then verified against that specification. When vendors publish a Certificate of Analysis (COA), it typically reports the measured purity and confirms the molecular weight matches the expected value for the sequence.
What has research examined?
Most of the published literature on BPC-157 is preclinical — meaning it comes from studies in rodents or in cell culture, not controlled human trials. Areas that researchers have investigated include:
- Tissue and tendon models
- Gastrointestinal-tract models
- Inflammation-related pathways
- Angiogenesis (blood-vessel formation) signaling
The largest share of this work sits in connective-tissue and musculoskeletal models. Rodent studies have examined the peptide in the context of tendon-, ligament-, muscle-, and bone-injury models, typically reporting laboratory endpoints such as markers of tissue organization or the expression of growth-associated factors at the site of injury. These are observations in controlled animal models — descriptions of what was measured under experimental conditions, not outcomes that have been demonstrated in people.
A second cluster of studies reflects the peptide's origins in gastric research. Because the BPC sequence was first characterized from a protein present in gastric juice, much of the early literature looked at gastrointestinal-tract models — for example, models of mucosal irritation or the response of the gut lining under various experimental stressors. Related preclinical papers have also explored gut–brain-axis signaling and vascular pathways in animals.
Across several of these models, authors frequently discuss angiogenesis — the formation of new blood vessels — as a candidate mechanism, often referencing signaling associated with vascular growth factors and nitric-oxide pathways. In the literature this is presented as a proposed mechanism still under investigation, not a settled or clinically validated one. A comparable point applies to the inflammation-related pathways above: the work measures markers in experimental systems rather than establishing a defined effect.
Mechanistically, papers in this area tend to frame BPC-157 as interacting with several signaling systems rather than a single receptor. Commonly referenced candidates include the growth-factor axis, the nitric-oxide system, and pathways linked to vascular growth. These proposed mechanisms are drawn from animal and cell experiments and remain hypotheses under study; none amounts to an established mode of action, and none has been confirmed in controlled human research.
A separate strand of reports concerns the molecule's stability and experimental handling rather than any biological outcome — how it behaves across different buffers, temperatures, and storage conditions, which is information researchers use when designing in-vitro work. Results of this kind are methodological: they describe BPC-157 as a research reagent and say nothing about activity in a person.
It is important to read all of this as descriptions of what has been studied, not as claims of effect in humans. The gap between promising animal data and demonstrated human outcomes is large: controlled human clinical trials of BPC-157 are essentially absent from the peer-reviewed record, and preclinical signals routinely fail to translate. Reviews of this literature also note recurring limitations — much of it originates from a small number of research groups, model systems and dosing vary widely, and reporting standards differ from those expected of clinical research. The appropriate reading is therefore "here is what has been examined in animals and cells," not "here is what BPC-157 does in humans." For BPC-157 that gap has not been closed by rigorous clinical trials, and nothing in the research base establishes a benefit, dose, or safety profile for human use.
How is it characterized and tested?
In a research context, two questions matter most about any peptide sample: is it the right molecule, and how pure is it. Those are answered by analytical testing — commonly HPLC for purity and mass spectrometry for identity. A published COA from an independent lab lets a researcher verify both before use. For more on this, see our guide on peptide handling and storage.
Common questions
Is BPC-157 the same as a naturally occurring compound?
No. It is a synthetic fragment based on a partial sequence found in a stomach protein, not a substance harvested from the body. Research-grade BPC-157 is manufactured to a defined specification.
Is BPC-157 approved for human use?
No. It has not been approved by the FDA and is not a medicine. It is studied in research settings only.
How should research-grade BPC-157 be stored?
General practice is to keep lyophilized peptide cold and protected from light and moisture, with different handling once reconstituted. See peptide handling and storage for the reasoning behind each step.